--Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today ...
-- Preliminary unaudited net revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results